title: Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease.
abstract: BACKGROUND
  Acetylcholinesterase inhibitors (AChEIs) are the treatment of choice for patients with Alzheimer's disease (AD). However, their efficacy is moderate and differs from patient to patient. Recent studies suggest that the Q192R variant of the paraoxonase 1 gene (PON1) might affect individual susceptibility to these drugs.
  
  
  METHODS
  We investigated the influence of 3 single nucleotide polymorphisms (SNPs) in PON1 (rs 662, rs 854560, rs 705381) and the APOE common polymorphism in 101 Polish patients with late-onset AD in response to treatment with AChEIs.
  
  
  RESULTS
  No significant differences were observed between carriers and non-carriers of the PON1 SNPs or the APOE common polymorphism in terms of treatment response. These results did not change after stratification of APOE status.
  
  
  CONCLUSIONS
  Our results suggest that both the investigated PON1 and APOE common SNPs do not influence treatment response to AChEIs in patients with AD.
authors.affiliation: Department of Neurology, University Hospital, Cracow, Poland. Aleksandra.Klimkowicz @ mp.pl
authors.forename: A
authors.initials: A
authors.lastname: Klimkowicz-Mrowiec
authors.forename: M
authors.initials: M
authors.lastname: Marona
authors.forename: K
authors.initials: K
authors.lastname: Spisak
authors.forename: J
authors.initials: J
authors.lastname: Jagiella
authors.forename: P
authors.initials: P
authors.lastname: Wolkow
authors.forename: A
authors.initials: A
authors.lastname: Szczudlik
authors.forename: A
authors.initials: A
authors.lastname: Slowik
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics*; D001057:Apolipoproteins E / Q000235:genetics; D043303:Aryldialkylphosphatase / Q000235:genetics*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004247:DNA / Q000235:genetics; D000077265:Donepezil; D005260:Female; D006239:Haplotypes; D006579:Heterozygote; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008297:Male; D009483:Neuropsychological Tests; D048448:Phenylcarbamates / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D060888:Real-Time Polymerase Chain Reaction; D000068836:Rivastigmine
chemical_list: D001057:Apolipoproteins E; D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D000077265:Donepezil; D004247:DNA; D043303:Aryldialkylphosphatase; D000068836:Rivastigmine